Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 30;41(5):111528. doi: 10.1016/j.celrep.2022.111528

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Comparison of binding epitopes, genetic characteristics, and neutralizing activity of NA8 and NE12 with clinically approved monoclonal antibodies

(A) Amino acid sequences of the receptor-binding domain (RBD) of Omicron sublineages BA.1 and BA.2 with mutations colored in red compared with the sequence of the original North American founder strain WA-1 (GenBank: MN985325); the asterisks indicate residues that contact the ACE receptor. The binding epitopes of different mAbs are presented below and highlighted in different colors.

(B) Surface representation of the RBD with the epitopes of NA8 (green line) and NE12 or clinically approved monoclonal antibodies (blue line) highlighted. Surface areas corresponding to the RBD residues mutated in the Omicron BA.1 sublineage are colored in magenta.

(C) Characteristics of NA8 and NE12 in comparison with clinically approved mAbs against SARS-CoV2.

HHS Vulnerability Disclosure